Drug Database
RE

remogliflozin etabonate + vildagliptin (Remozen V / Remo V)

✓ Approved

Glenmark Pharmaceuticals Limited · DPP4 · 小分子

什么是 remogliflozin etabonate + vildagliptin?

remogliflozin etabonate + vildagliptin 是一种小分子,由Glenmark Pharmaceuticals Limited研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Remozen V, Remo V
公司Glenmark Pharmaceuticals Limited
药物类别小分子
分子靶点DPP4, SLC5A2
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

remogliflozin etabonate + vildagliptin 作用于 2 个分子靶点:

DPP4dipeptidyl peptidase 4 (CD26, DPPIV)
SLC5A2solute carrier family 5 member 2 (SGLT2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

remogliflozin etabonate + vildagliptin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

相关研究文献

PubMedFrontiers in pharmacology2026-11-17

Comparative efficacy and safety of topical olopatadine formulations for allergic conjunctivitis: a systematic review and network meta-analysis.

Li Caiju C, Gao Yuying Y, Wei Lijuan L

Allergic conjunctivitis (AC) affects 15%-40% of the global population. Traditional network meta-analyses often group different formulations of olopatadine into a single node, obscuring concentration-dependent variations. This network meta-analysis evaluated the relative efficacy and safety of distinct olopatadine concentrations (0.1%, 0.2%, 0.77%) against other topical anti-allergic or anti-inflammatory agents. Registered in PROSPERO (CRD420261375330), this study systematically searched major databases up to 1 May 2026, for randomized controlled trials (RCTs) on adults with AC. Interventions evaluated olopatadine formulations (0.1% BID, 0.2% QD, 0.77% QD) as independent nodes alongside 0.05% epinastine, 0.025% ketotifen, 0.25% alcaftadine, 1.5% bepotastine, 0.2% loteprednol etabonate, or placebo. Frequentist random-effects network meta-analyses were performed. Nineteen randomized controlled trials (RCTs) encompassing 2,745 patients (5,141 eyes) were analyzed. For ocular itching (18 RCTs), 0.77% olopatadine demonstrated superior efficacy among dual-acting agents (SUCRA = 80.7%), significantly outperforming epinastine and ketotifen. For conjunctival hyperemia (17 RCTs), 0.25% alcaftadine demonstrated the highest likelihood of efficacy (SUCRA = 66.5%), whereas among olopatadine formulations, only 0.2% significantly outperformed placebo (SUCRA = 47.4%). Subgroup analyses showed that 0.77% olopatadine and 0.25% alcaftadine were particularly effective against acute itching in conjunctival allergen challenge models. Safety assessments across 11 RCTs yielded wide confidence intervals due to data sparsity, precluding definitive tolerability rankings. Although trial data predominantly reported mild adverse events, external evidence highlights key long-term safety concerns, notably intraocular pressure elevation associated with extended topical corticosteroid therapy such as 0.2% loteprednol etabonate. Topical dual-acting agents demonstrate outcome-specific efficacy variations in allergic conjunctivitis management. Olopatadine 0.77% excels in pruritus control, whereas alcaftadine 0.25% provides the highest likelihood of hyperemia resolution. Clinical management should adopt a personalized step-ladder approach: utilizing potent once-daily dual-acting agents (0.77% olopatadine or 0.25% alcaftadine) as first-line therapy for acute or seasonal exposure. Short-term topical corticosteroids (such as 0.2% loteprednol etabonate) should be strictly reserved for severe natural exposure non-responsive to dual-acting agents, with mandatory intraocular pressure monitoring, before transitioning back to dual-acting maintenance.

PMID 43042078
阅读全文 →
PubMedDermatology (Basel, Switzerland)2026-11-06

Dipeptidyl Peptidase-4 Inhibitors and Bullous Pemphigoid: A Danish Nationwide Case-Control Study.

Ahle Erichsen Philip P, Heerfordt Ida M IM, Huan Olsen Rasmus R, Mogensen Mette M et al.

Anti-diabetic dipeptidyl peptidase-4 inhibitors (DPP-4i) are associated with an increased risk of bullous pemphigoid (BP), but Danish population-based data, including product specific estimates, are lacking. We conducted a nationwide matched case-control study in Denmark of incident BP cases diagnosed between 2007 and 2024. BP cases were matched 1:100 to population controls using risk set sampling based on age, sex, and index date. DPP-4i exposure was defined as at least one redeemed prescription before the index date (ever use) or during the preceding three months (current use). In a specificity analysis, we compared DPP-4i users and users of other type 2 antidiabetics without DPP-4i use with non-users of type 2 diabetes medications. Odds ratios (ORs) with 95% CIs were estimated using conditional logistic regression. We identified 2,497 incident BP cases and 249,700 controls (median age 78 years). DPP-4i exposure was more common among BP cases for both ever use (OR: 3.81, 95% CI: 3.31-4.40) and current use (OR: 5.59, 95% CI: 4.70-6.63). For current use, the highest odds ratios were observed for vildagliptin (OR: 10.82, 95% CI: 6.73-17.41) and linagliptin (OR: 9.86, 95% CI: 7.33-13.25), whereas the estimate for sitagliptin was lower (OR: 2.46, 95% CI: 1.65-3.66). In the specificity analysis, other antidiabetic therapies did not show a similarly increased risk of BP. In the Danish population there was a strong association between DPP-4i use and incident BP. This was most pronounced for vildagliptin and linagliptin while the signal was weaker for sitagliptin.

PMID 42993181
阅读全文 →
PubMedSAR and QSAR in environmental research2026-10-29

Integrating QSAR, molecular dynamics and MM-GBSA to re-rank natural product-derived DPP4 candidates from virtual screening.

Aktaş E E

Dipeptidyl peptidase-4 (DPP4) is a validated target for type 2 diabetes, and virtual screening of natural product libraries is a common route to new chemotypes. We asked whether a top docking rank survives independent scrutiny. From COCONUT, 85,600 compounds were filtered to 32,008 and docked against DPP4; 873 outscored the crystallographic ligand N7F (-10.01 kcal/mol), with Lig_771 first at -12.5 kcal/mol. Across four 300 ns simulations (two replicas per complex, 1.2 μs) Lig_771 stayed bound but never reproduced the gliptin recognition motif: the control held its salt bridges to Glu205 and Glu206 in over 93% of frames, whereas Lig_771 formed no persistent hydrogen bond to these residues and sampled two distinct poses. MM-GBSA gave -15.6 kcal/mol for Lig_771 against -23.9 for the control. A QSAR model built on 4327 measured DPP4 inhibitors (scaffold-based external R2 = 0.415; random split 0.669) predicted a pIC50 of 6.59 for Lig_771, below linagliptin (8.29), sitagliptin (7.39) and vildagliptin (6.96). None of the three analyses corroborated the docking ranking. The study is computational and does not establish DPP4 inhibition. Lig_771 occupies largely unexplored chemical space (maximum Tanimoto similarity 0.316) and merits testing, but selecting hits on docking score alone would have been misleading here.

PMID 42954798
阅读全文 →
PubMedJournal of molecular histology2026-10-21

Effects of topical vildagliptin versus triamcinolone acetonide on experimentally induced hypertrophic scars in a rabbit model.

Nasser Zaynab Ali ZA, Jaafar Farrah Rasool FR

The present study aimed to evaluate the effects of topical vildagliptin on experimentally induced hypertrophic scars (HTSs) in a rabbit model. A total of 40 healthy male albino rabbits were randomly assigned to five groups (n = 8): healthy control (CTRL), untreated induced HTS model (HTS model), vehicle-received (VEH), 0.1% triamcinolone acetonide-treated (TAC), and 3% vildagliptin-treated (VIL). On day 0, four full-thickness wounds extending to the cartilage were created on the ventral surface of each rabbit ear using an 8-mm biopsy punch. On day 30, topical treatment was initiated on the newly formed scars and continued twice daily for 21 days. Samples were collected on day 51 post-wounding. Outcome measures included molecular quantification of collagen type 1 (Col I), collagen type 3 (Col III), transforming growth factor-beta 1 (TGF-β1), interleukin 6 (IL-6), histopathological examination, and alpha-smooth muscle actin (α-SMA) immunoreactivity. Vildagliptin significantly reduced Col I, Col III, TGF-β1, and IL-6 compared with the HTS model group (p < 0.001). Histopathological analysis revealed a marked improvement in scar architecture, as evidenced by lower histopathological scores and a reduced scar elevation index. Masson's trichrome (MT) staining demonstrated a significant reduction in collagen deposition, accompanied by partial restoration of normal collagen fiber organization. Immunohistochemical analysis revealed no significant change in α-SMA immunoreactivity. This more likely reflects a potential incomplete suppression of myofibroblasts. Overall, these findings suggest that topical vildagliptin may represent a promising therapeutic approach for the treatment of HTSs.

PMID 42902087
阅读全文 →
PubMedFrontiers in immunology2026-10-20

Effect of immunosuppressive drugs on glucose-stimulated insulin secretion: concentration-response studies in dynamic perifusion assays.

Chuang Sung-Ting ST, Watts Brandon B, Alcazar Oscar O, Buchwald Peter P

Immunosuppressive drugs, which are required to maintain graft function in transplant recipients, are associated with many unavoidable side effects including posttransplant diabetes mellitus (PTDM) that involves both peripheral insulin resistance and impairment of insulin secretion. To characterize in detail the concentration-dependency of the effect of well-known immunosuppressive drugs on glucose-stimulated insulin secretion (GSIS), we performed dynamic perifusion studies with human pancreatic islets. The effect on the time-profile of GSIS has been assessed over a wide concentration range for several clinically relevant immunomodulatory therapies, including small-molecule drugs (cyclosporine, sirolimus, tacrolimus, prednisolone acetate, and loteprednol etabonate) and biologics (abatacept and anti-CD40L), plus a prospective β-cell proliferation-inducing agent (harmine). While biologics showed no significant detrimental effects after one-day treatment even at relatively high concentrations (5 µM), all small-molecule drugs inhibited insulin secretion in a concentration-dependent manner, although glucocorticoids showed a distinct response pattern. Calcineurin and mTOR inhibitors preserved GSIS within their therapeutic ranges but progressively distorted its time-profile at higher concentrations and completely suppressed secretion at the highest levels, where they were also cytotoxic. Cyclosporine exhibited the least, only about 35-fold, separation between its therapeutic target (C targ) and half-maximal GSIS inhibitory (IC50) concentrations. Glucocorticoids did not alter the shape of the time-profile but inhibited overall insulin secretion even at therapeutic levels without affecting islet viability. Their inhibitory effect only increased slowly with concentration and did not follow a classic sigmoid pattern that has unity Hill slope. These findings establish quantitative benchmarks for immunosuppressant-induced β-cell toxicity and provide a framework for optimizing immunosuppressive regimens to reduce the risk of PTDM.

PMID 42898311
阅读全文 →
PubMedImmunopharmacology and immunotoxicology2026-10-11

Vildagliptin attenuates thioacetamide-induced hepatic fibrosis in rats: associations with AMPK/SIRT1/Nrf2 and STAT3/TGF-β1 signaling.

Almikhlafi Mohannad A MA, Alsayb May A MA, Almadani Sara A SA, Saeedi Tahani T et al.

Liver fibrosis is a progressive consequence of chronic injury with limited treatment options. Vildagliptin (Vilda), a dipeptidyl peptidase-4 inhibitor, possesses antioxidant and anti-inflammatory properties, but its effects on thioacetamide (TAA)-induced liver fibrosis are not fully characterized. This study evaluated Vilda in TAA-treated male rats by assessing hepatic function, oxidative stress, and signaling markers. Rats received TAA (100 mg/kg, i.p., twice weekly for 6 weeks) alone or with Vilda (10 or 20 mg/kg, p.o., daily during weeks 3-6). Serum biochemistry, hepatic antioxidants, and specific protein concentrations (AMPK, p-AMPK, SIRT1, Nrf2, STAT3, p-STAT3, TGF-β1, and AFP) were measured. Liver sections were assessed via H&E, qualitative Masson's trichrome, and immunohistochemistry for p-AKT and SIRT1. TAA impaired liver function, altered lipid profiles, increased oxidative stress, and induced histopathological injury with collagen deposition. These changes coincided with altered hepatic AMPK/SIRT1/Nrf2 and STAT3/TGF-β1-associated markers, alongside PGC-1α and KEAP1 mRNA expression. Vilda treatment was associated with dose-dependent improvements in biochemical, oxidative-stress, and histopathological findings, alongside shifts in inflammation- and fibrosis-associated markers. Vilda was also associated with increased SIRT1 and reduced p-AKT immunoreactivity. Vilda treatment was associated with attenuation of TAA-induced hepatic injury and fibrotic changes in parallel with modulation of AMPK/SIRT1/Nrf2 and STAT3/TGF-β1-related markers. Because quantitative collagen morphometry and pathway-intervention experiments were not performed, these findings represent associations rather than confirmed causal mechanisms. Further studies are required to define the precise molecular interactions and translational potential of Vilda as an antifibrotic agent.

PMID 42858114
阅读全文 →

注册免费账户还可查看另外 1642 篇文献

免费注册查看全部文献 →

了解更多remogliflozin etabonate + vildagliptin